Yue Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yue Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Haiyang Dong
Shanghai Stomatological Hospital & School of Stomatology, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
3 shared publications- Liang Sun
Shanghai Stomatological Hospital & School of Stomatology, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
3 shared publications - Xiang Gao
Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
3 shared publications Xinming Xu
Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
3 shared publicationsZhicheng Zhang
Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Fudan University, Shanghai, China
3 shared publicationsHuan Yu
Sleep and Wake Disorders Center, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103338
Associations of Physical Activity and Diet Quality With Mortality and Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome
- 13 October 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103338
Open AccessAssociations of Physical Activity and Diet Quality With Mortality and Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome
- Open Access
- 18 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101406
Misalignment Between Circadian Preference and Accelerometer-Derived Sleep-Wake Cycle With Increased Risk of Cardiometabolic Diseases
- 18 November 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (12) , 101406
Open AccessMisalignment Between Circadian Preference and Accelerometer-Derived Sleep-Wake Cycle With Increased Risk of Cardiometabolic Diseases
- Open Access
Misalignment between circadian preference and accelerometer-derived actual sleep-wake cycle is associated with increased risk of cardiometabolic diseases: a prospective cohort study in UK Biobank
Background Evidence has linked several circadian disruption indicators, such as social jetlag and shift work, to adverse health outcomes, however, associations of misalignment between circadian preference and actual sleep-wake cycle with cardiometabolic diseases (CMDs) remains unclear. We aimed to prospectively investigate the associations of the circadian misalignment with CMDs including type 2 diabetes (T2D), chronic heart diseases (CHD), and stroke, and to uncover potential mechanisms linking circadian misalignment and CMDs. Methods A total of 60,965 participants from the UK Biobank study without baseline CMDs and followed-up for an average of 7.9 years were included in the current analysis. Circadian misalignment was defined as discrepancies between self-reported chronotype and accelerometer-derived midpoint of sleep to detect its association with CMDs. Incident CMDs were derived from primary care, hospital inpatient, death registry, and self-reported source of data. Cox proportional hazards regression models were used to compute the hazard ratio (HR) and confidence intervals (CIs) on the association between circadian misalignment (quintiles of residuals of midsleep on chronotype) and incident CMDs. Results U-shaped associations were found of the circadian misalignment with incident T2D and CHD after adjusting the potential confounders. Compared to individuals with aligned midsleep and circadian preferences (Q3), those with advanced and delayed circadian misalignment had higher risks of T2D [HR (95%CI) 1.22 (1.03, 1.45) in Q1 and 1.39 (1.18, 1.62) in Q5]. However, only delayed circadian misalignment was significantly associated with an increased risk of CHD [HR (95%CI) 1.15 (1.01, 1.31) in Q4 and 1.16 (1.02, 1.33) in Q5]. Liver function, lipid and glucose metabolism, and inflammatory markers partially explained the observed circadian misalignment and CMDs association (mediation proportion 12.3-44.6% for T2D, 8.8-20.5% for CHD). Moreover, the association between delayed circadian misalignment and CMDs was more prominent in women (for T2D, Pinteraction=0.03) and in younger adults (for CHD, Pinteraction=0.02) compared to their counterparts. Additionally, early chronotype [HR (95%CI): 1.19 (1.06, 1.34)] rather than late chronotype was associated with an increased risk of incident T2D. Conclusion Both advanced and delayed circadian misalignment were associated with increased risks of CMDs, suggesting potential benefits of aligning actual sleep-wake cycles with individual circadian preferences. What is known? Cardiometabolic diseases such as type 2 diabetes, coronary heart disease, and cerebrovascular diseases have become major concerns in global public health over recent decades. Evidence has linked several circadian disruption indicators to adverse health outcomes: People living with late chronotype (circadian preference), late sleep timing, long social jetlag (the difference between midsleep on work-free days and work days), and shift work were prone to introduce circadian disruptions and had higher risks of cardiometabolic diseases. Little is known about whether and how the misalignment between circadian preference and actual sleep-wake cycle is associated with cardiometabolic diseases, particularly in large prospective cohort studies. What New Information Does This Article Contribute? This is the first study to propose a new metrics (misalignment between circadian preference and actual sleep-wake cycle) to shed some lights on quantifying human circadian disruption in general population of differed work schedule and in population with less disrupted circadian rhythm. Both advanced and delayed sleep-wake cycle comparing to individual circadian preference were associated with increased risks of cardiometabolic diseases. Population may benefit from keeping an actual sleep-wake cycle in accordance with their circadian preference. Early chronotype rather than late chronotype were found to associate with an increased risk of incident T2D, independent of actual sleep-wake cycle. Age and sex modified the associations between circadian misalignment and cardiometabolic diseases, while liver function, lipid and glucose metabolism, and inflammatory markers partially mediated the associations.
Open AccessMisalignment between circadian preference and accelerometer-derived actual sleep-wake cycle is associated with increased risk of cardiometabolic diseases: a prospective cohort study in UK Biobank
Background Evidence has linked several circadian disruption indicators, such as social jetlag and shift work, to adverse health outcomes, however, associations of misalignment between circadian preference and actual sleep-wake cycle with cardiometabolic diseases (CMDs) remains unclear. We aimed to prospectively investigate the associations of the circadian misalignment with CMDs including type 2 diabetes (T2D), chronic heart diseases (CHD), and stroke, and to uncover potential mechanisms linking circadian misalignment and CMDs. Methods A total of 60,965 participants from the UK Biobank study without baseline CMDs and followed-up for an average of 7.9 years were included in the current analysis. Circadian misalignment was defined as discrepancies between self-reported chronotype and accelerometer-derived midpoint of sleep to detect its association with CMDs. Incident CMDs were derived from primary care, hospital inpatient, death registry, and self-reported source of data. Cox proportional hazards regression models were used to compute the hazard ratio (HR) and confidence intervals (CIs) on the association between circadian misalignment (quintiles of residuals of midsleep on chronotype) and incident CMDs. Results U-shaped associations were found of the circadian misalignment with incident T2D and CHD after adjusting the potential confounders. Compared to individuals with aligned midsleep and circadian preferences (Q3), those with advanced and delayed circadian misalignment had higher risks of T2D [HR (95%CI) 1.22 (1.03, 1.45) in Q1 and 1.39 (1.18, 1.62) in Q5]. However, only delayed circadian misalignment was significantly associated with an increased risk of CHD [HR (95%CI) 1.15 (1.01, 1.31) in Q4 and 1.16 (1.02, 1.33) in Q5]. Liver function, lipid and glucose metabolism, and inflammatory markers partially explained the observed circadian misalignment and CMDs association (mediation proportion 12.3-44.6% for T2D, 8.8-20.5% for CHD). Moreover, the association between delayed circadian misalignment and CMDs was more prominent in women (for T2D, Pinteraction=0.03) and in younger adults (for CHD, Pinteraction=0.02) compared to their counterparts. Additionally, early chronotype [HR (95%CI): 1.19 (1.06, 1.34)] rather than late chronotype was associated with an increased risk of incident T2D. Conclusion Both advanced and delayed circadian misalignment were associated with increased risks of CMDs, suggesting potential benefits of aligning actual sleep-wake cycles with individual circadian preferences. What is known? Cardiometabolic diseases such as type 2 diabetes, coronary heart disease, and cerebrovascular diseases have become major concerns in global public health over recent decades. Evidence has linked several circadian disruption indicators to adverse health outcomes: People living with late chronotype (circadian preference), late sleep timing, long social jetlag (the difference between midsleep on work-free days and work days), and shift work were prone to introduce circadian disruptions and had higher risks of cardiometabolic diseases. Little is known about whether and how the misalignment between circadian preference and actual sleep-wake cycle is associated with cardiometabolic diseases, particularly in large prospective cohort studies. What New Information Does This Article Contribute? This is the first study to propose a new metrics (misalignment between circadian preference and actual sleep-wake cycle) to shed some lights on quantifying human circadian disruption in general population of differed work schedule and in population with less disrupted circadian rhythm. Both advanced and delayed sleep-wake cycle comparing to individual circadian preference were associated with increased risks of cardiometabolic diseases. Population may benefit from keeping an actual sleep-wake cycle in accordance with their circadian preference. Early chronotype rather than late chronotype were found to associate with an increased risk of incident T2D, independent of actual sleep-wake cycle. Age and sex modified the associations between circadian misalignment and cardiometabolic diseases, while liver function, lipid and glucose metabolism, and inflammatory markers partially mediated the associations.
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (12) , 3641-3652
KLRB1 is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration
Background: Endometrial cancer (EC) has the characteristics of high mortality and poor prognosis in the advanced stage, which seriously threatens women’s health. Killer cell lectin-like receptor B1 (KLRB1) is a promising immune checkpoint of which the expression level can regulate the killing effect on tumor cells of the immune system, thereby affecting the survival and prognosis of tumor patients. However, it is still unclear whether KLRB1 is associated with survival and prognosis in patients with EC. Therefore, our study focused on the relationship between KLRB1 and immune cells to explore the role of KLRB1 on the immune microenvironment, and to further explore its feasibility as a prognostic marker in EC. Methods: In this study, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were used to analyze the messenger RNA (mRNA) expression level of KLRB1 in normal endometrial and EC tissues. The University of Alabama at Birmingham Cancer data analysis Portal (UALCAN) database was used to determine the correlation between KLRB1 mRNA expression and clinical features among the EC patients. KLRB1 expression levels were investigated in the Tumor IMmune Estimation Resource (TIMER) database to reveal its relationship with immune cell infiltration of EC. Finally, using the R package clusterProfiler, enrichment analysis was performed on KLRB1 to study its potential function. Results: The results suggested that KLRB1 expression varied in different tumor tissues, and the EC group had lower mRNA expression levels than did the control group. It was also found that patients with high expression of KLRB1 had a better prognosis. According to further enrichment and immune infiltration analyses, KLRB1 expression had a closed relationship with the level of infiltration of some immune cell types, such as B cells memory, eosinophils, and Tregs, among others. Conclusions: KLRB1 expression is associated with the infiltration of immune cells and can be used as a prognostic biomarker in EC.
- 1 December 2023
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 12 (12) , 3641-3652
Open AccessKLRB1 is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration
Background: Endometrial cancer (EC) has the characteristics of high mortality and poor prognosis in the advanced stage, which seriously threatens women’s health. Killer cell lectin-like receptor B1 (KLRB1) is a promising immune checkpoint of which the expression level can regulate the killing effect on tumor cells of the immune system, thereby affecting the survival and prognosis of tumor patients. However, it is still unclear whether KLRB1 is associated with survival and prognosis in patients with EC. Therefore, our study focused on the relationship between KLRB1 and immune cells to explore the role of KLRB1 on the immune microenvironment, and to further explore its feasibility as a prognostic marker in EC. Methods: In this study, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were used to analyze the messenger RNA (mRNA) expression level of KLRB1 in normal endometrial and EC tissues. The University of Alabama at Birmingham Cancer data analysis Portal (UALCAN) database was used to determine the correlation between KLRB1 mRNA expression and clinical features among the EC patients. KLRB1 expression levels were investigated in the Tumor IMmune Estimation Resource (TIMER) database to reveal its relationship with immune cell infiltration of EC. Finally, using the R package clusterProfiler, enrichment analysis was performed on KLRB1 to study its potential function. Results: The results suggested that KLRB1 expression varied in different tumor tissues, and the EC group had lower mRNA expression levels than did the control group. It was also found that patients with high expression of KLRB1 had a better prognosis. According to further enrichment and immune infiltration analyses, KLRB1 expression had a closed relationship with the level of infiltration of some immune cell types, such as B cells memory, eosinophils, and Tregs, among others. Conclusions: KLRB1 expression is associated with the infiltration of immune cells and can be used as a prognostic biomarker in EC.
- Open Access
- 24 August 2018
- Vol. 19 (8) , 2043-2055
Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach
Objective:According to current guidelines, there is no clear second-line treatment for advanced liver cancer.In practice, clinicians have attempted to use thalidomide(TLD) combined with transcatheter arterial chemoembolization(TACE) for treating liver cancer. This study aims to assess the clinical efficacy and safety of TLD combined with TACEin patients with intermediate or advanced hepatocellular carcinoma. Methods: Medline, Embase, the Cochrane CentralRegister of Controlled Trials (CENTRAL), database of ClinicalTrials.gov, CBM, CNKI, VIP and Wanfang databasewere searched for eligible studies. Criteria for inclusion in our meta-analysis included a study that patients diagnosedwith intermediate or advanced HCC, the use of TACE plus TLD or its derivatives, and the availability of outcomedata for survival. A meta-analysis was conducted to summarize the evidences of randomized controlled trials (RCTs).And finally, the GRADE approach was used to assess the quality of these evidences. Results: Twelve RCTs involving894 Hepatocellular Carcinoma (HCC) patients were included. The meta-analysis results showed that TACE plus TLD wassignificantly superior than TACE alone in terms of 12-month survival rate (OR=2.55, 95% CI:1.78-3.64, P<0.01), 24-monthsurvival rate (OR=2.95, 95% CI:1.96-4.44, P<0.01), 36-month survival rate (OR=2.95, 95% CI:1.41-6.19, P<0.004),progression-free survival (PFS) (MD=2.23, 95% CI:1.19-3.28 , P<0.001), objective response rate (OR=1.84, 95%CI:1.34-2.52, P<0.0001), and disease control rate (OR=2.68, 95% CI:1.80-3.99). Subgroup analysis demonstratedno differences across related outcomes. Sensitivity analyses showed no important differences in the estimates ofeffects. Quality of evidence for all outcomes was rated moderate to very low after applying GRADE approach.Conclusions: Current evidence seemed to support the suggestion that TACE plus TLD as the second line treatment forpatients with intermediate or advanced HCC. However, this finding is not definitive due to the poor quality of includedstudies, more carefully designed and conducted RCTs are warranted to confirm above conclusions.
- 24 August 2018
- Vol. 19 (8) , 2043-2055
Open AccessThalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach
Objective:According to current guidelines, there is no clear second-line treatment for advanced liver cancer.In practice, clinicians have attempted to use thalidomide(TLD) combined with transcatheter arterial chemoembolization(TACE) for treating liver cancer. This study aims to assess the clinical efficacy and safety of TLD combined with TACEin patients with intermediate or advanced hepatocellular carcinoma. Methods: Medline, Embase, the Cochrane CentralRegister of Controlled Trials (CENTRAL), database of ClinicalTrials.gov, CBM, CNKI, VIP and Wanfang databasewere searched for eligible studies. Criteria for inclusion in our meta-analysis included a study that patients diagnosedwith intermediate or advanced HCC, the use of TACE plus TLD or its derivatives, and the availability of outcomedata for survival. A meta-analysis was conducted to summarize the evidences of randomized controlled trials (RCTs).And finally, the GRADE approach was used to assess the quality of these evidences. Results: Twelve RCTs involving894 Hepatocellular Carcinoma (HCC) patients were included. The meta-analysis results showed that TACE plus TLD wassignificantly superior than TACE alone in terms of 12-month survival rate (OR=2.55, 95% CI:1.78-3.64, P<0.01), 24-monthsurvival rate (OR=2.95, 95% CI:1.96-4.44, P<0.01), 36-month survival rate (OR=2.95, 95% CI:1.41-6.19, P<0.004),progression-free survival (PFS) (MD=2.23, 95% CI:1.19-3.28 , P<0.001), objective response rate (OR=1.84, 95%CI:1.34-2.52, P<0.0001), and disease control rate (OR=2.68, 95% CI:1.80-3.99). Subgroup analysis demonstratedno differences across related outcomes. Sensitivity analyses showed no important differences in the estimates ofeffects. Quality of evidence for all outcomes was rated moderate to very low after applying GRADE approach.Conclusions: Current evidence seemed to support the suggestion that TACE plus TLD as the second line treatment forpatients with intermediate or advanced HCC. However, this finding is not definitive due to the poor quality of includedstudies, more carefully designed and conducted RCTs are warranted to confirm above conclusions.
- Open Access
- 25 July 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22553
Enzyme-Linked Immunosorbent Assay-Format Tissue Culture Infectious Dose-50 Test for Titrating Dengue Virus
A dengue nonstructural protein 1 (NS1) antigen capture enzyme-linked immunosorbent assay (ELISA)-based tissue culture infectious dose-50 (TCID50) test (TCID50-ELISA) was developed as an alternative to the standard plaque assay for titrating dengue virus. Virus titers obtained by TCID50-ELISA were comparable to those obtained by the plaque assay and by the traditional TCID50-cytopathic effect (CPE) test (TCID50-CPE), with a better reproducibility and a lower coefficient of variation. Quantitative comparison of TCID50-ELISA and TCID50-CPE resulted in a correlation coefficient of 0.976. Moreover, this new method showed a wider application to C6/36, Vero E6, BHK-21, and Vero cells compared with other titration methods. In summary, the novel TCID50-ELISA method described here provides a more reliable and more accurate alternative compared to the plaque assay and TCID50-CPE for titration of dengue virus.
- 25 July 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22553
Open AccessEnzyme-Linked Immunosorbent Assay-Format Tissue Culture Infectious Dose-50 Test for Titrating Dengue Virus
A dengue nonstructural protein 1 (NS1) antigen capture enzyme-linked immunosorbent assay (ELISA)-based tissue culture infectious dose-50 (TCID50) test (TCID50-ELISA) was developed as an alternative to the standard plaque assay for titrating dengue virus. Virus titers obtained by TCID50-ELISA were comparable to those obtained by the plaque assay and by the traditional TCID50-cytopathic effect (CPE) test (TCID50-CPE), with a better reproducibility and a lower coefficient of variation. Quantitative comparison of TCID50-ELISA and TCID50-CPE resulted in a correlation coefficient of 0.976. Moreover, this new method showed a wider application to C6/36, Vero E6, BHK-21, and Vero cells compared with other titration methods. In summary, the novel TCID50-ELISA method described here provides a more reliable and more accurate alternative compared to the plaque assay and TCID50-CPE for titration of dengue virus.